Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 22, 2024

SELL
$1.31 - $1.86 $13,100 - $18,600
-10,000 Reduced 40.0%
15,000 $23.6 Million
Q3 2023

Nov 21, 2023

BUY
$1.23 - $2.45 $30,750 - $61,250
25,000 New
25,000 $45.5 Million

Others Institutions Holding BLRX

About BioLineRx Ltd.


  • Ticker BLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,524,500
  • Market Cap $29.5M
  • Description
  • BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...
More about BLRX
Track This Portfolio

Track Allen Mooney & Barnes Investment Advisors LLC Portfolio

Follow Allen Mooney & Barnes Investment Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allen Mooney & Barnes Investment Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allen Mooney & Barnes Investment Advisors LLC with notifications on news.